Literature DB >> 8819799

Familial occurrence and inheritance studies in inflammatory bowel disease.

V Binder1, M Orholm.   

Abstract

A number of studies have demonstrated aggregation of cases of ulcerative colitis or Crohn's disease in families, and of cases of both diseases within the same families, suggesting that patients share a genetic background. Perhaps because of differences in the selection of patients, study design and diagnostic criteria, different patterns of occurrence of inflammatory bowel disease (IBD) have been found among relatives of patients with these disorders. In recent years, however, several studies have been carried out, aiming by epidemiological methods to reveal (1) the frequency of familial occurrence of IBD among patients with ulcerative colitis and Crohn's disease, and (2) the prevalence of IBD among 1(0) relatives to patients with these diseases. Results from these studies show a relatively uniform pattern of family occurrence in about 10% of patients with ulcerative colitis and Crohn's disease, and a prevalence among 1(0) relatives of about 10 times that of the background population. A twin study reported a significantly higher concordance rate for Crohn's disease than for ulcerative colitis in monozygotic twins. By use of complex segregation analyses in 3 different studies, a very similar model of inheritance was found to fit for ulcerative colitis, namely a major dominant or additive gene with a low penetrance. For Crohn's disease the best-fitting model was a major recessive gene, with a high penetrance. This difference strongly supports the concept of ulcerative colitis and Crohn's disease as two separate disease entities. The occurrence of both diseases within the same families in certain members of the affected families is difficult to explain. The search for distinct associations of HLA genes with inflammatory bowel disease has shown a positive correlation between DR2 and ulcerative colitis and a negative association with DR4 and DRw6, compared with ethnically matched controls. In contrast, in Crohn's disease a positive association with the combination of DR1 and DQw5 alleles was revealed, thus indicating genetically different disease susceptibility for the two disorders. In general, however, no consistent pattern has been revealed from studies of association of HLA-A or -B antigens or blood group and serum protein markers. In two French families with several members affected with Crohn's disease no evidence for an HLA haplotype association could be revealed. Possible inherited markers of ulcerative colitis or Crohn's disease have been sought but without convincing success. Increased intestinal permeability, presence of anticolon antibodies and presence of antineutrophil leukocyte antibodies have been proposed, but not proved. Thorough studies are now needed of multimember families with disease for linkage studies to identify loci which contribute to increased liability. Such studies are in progress in different centres.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8819799     DOI: 10.1016/0300-2977(95)00093-3

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  10 in total

1.  Role of major histocompatibility complex class I-related molecules A*A5.1 allele in ulcerative colitis in Chinese patients.

Authors:  Min Lü; Bing Xia; Liuqing Ge; Yi Li; Jie Zhao; Fan Chen; Feng Zhou; Xiaolian Zhang; Jinquan Tan
Journal:  Immunology       Date:  2008-11-07       Impact factor: 7.397

2.  MICB0106 gene polymorphism is associated with ulcerative colitis in central China.

Authors:  Yi Li; Bing Xia; Min Lü; Liuqing Ge; Xiaolian Zhang
Journal:  Int J Colorectal Dis       Date:  2009-08-07       Impact factor: 2.571

3.  Immunopathogenesis of inflammatory bowel disease.

Authors:  Julien Matricon; Nicolas Barnich; Denis Ardid
Journal:  Self Nonself       Date:  2010-10

4.  MHC class I chain-related gene A-A5.1 allele is associated with ulcerative colitis in Chinese population.

Authors:  Yijuan Ding; Bing Xia; Min Lü; Yan Zhang; Jin Li; Mei Ye; Hesheng Luo; Jieping Yu; Xiaolian Zhang; Jingquan Tan
Journal:  Clin Exp Immunol       Date:  2005-10       Impact factor: 4.330

5.  Pyogenic arthritis, pyoderma gangrenosum, and acne syndrome maps to chromosome 15q.

Authors:  H B Yeon; N M Lindor; J G Seidman; C E Seidman
Journal:  Am J Hum Genet       Date:  2000-03-21       Impact factor: 11.025

Review 6.  Appendectomy does not decrease the risk of future colectomy in UC: results from a large cohort and meta-analysis.

Authors:  Alyssa Parian; Berkeley Limketkai; Joyce Koh; Steven R Brant; Alain Bitton; Judy H Cho; Richard H Duerr; Dermot P McGovern; Deborah D Proctor; Miguel D Regueiro; John D Rioux; Phil Schumm; Kent D Taylor; Mark S Silverberg; A Hillary Steinhart; Ruben Hernaez; Mark Lazarev
Journal:  Gut       Date:  2016-04-13       Impact factor: 23.059

Review 7.  Creating diseases to understand what prevents them: genetic analysis of inflammation in the gastrointestinal tract.

Authors:  Katharina Brandl; Bruce Beutler
Journal:  Curr Opin Immunol       Date:  2012-11-01       Impact factor: 7.486

Review 8.  Matrix metalloproteinases in inflammatory bowel disease: an update.

Authors:  Shane O'Sullivan; John F Gilmer; Carlos Medina
Journal:  Mediators Inflamm       Date:  2015-04-08       Impact factor: 4.711

9.  Activating Killer-cell Immunoglobulin-like Receptor genes confer risk for Crohn's disease in children and adults of the Western European descent: Findings based on case-control studies.

Authors:  Suzanne Samarani; David R Mack; Charles N Bernstein; Alexandre Iannello; Olfa Debbeche; Prevost Jantchou; Christophe Faure; Colette Deslandres; Devendra K Amre; Ali Ahmad
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

10.  Characteristic phenotypes in Korean Crohn's disease patients who underwent intestinal surgery for the treatment.

Authors:  Seung Hyuk Baik; Kyu Joo Park; Kang Young Lee; Yong Beom Cho; Gyu-Seog Choi; Kil Yeon Lee; Sang Nam Yoon; Chang Sik Yu
Journal:  J Korean Med Sci       Date:  2013-03-27       Impact factor: 2.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.